https://orcid.org/0000-0001-7507-6999
References
- Zuberbier T, Aberer W, Asero R, et al. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393–1414.
- Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther 2015;25:9:4909–15.
- Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol 2012;12:406–411.
- Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015;135:337–342.
- Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017;72:519–533.
- Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics 2017;7:1266–1276.
- Tonacci A, Billeci L, Pioggia G, et al. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature. Pharmacotherapy 2017;37:464–480.
- Francés L, Leiva-Salinas M, Silvestre JF. Omalizumab in the treatment of chronic urticaria. Actas Dermosifiliogr 2014;105:45–52.
- Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol 2015;115:126–129.
- Göncü EK, Aktan S, Atakan N, et al. Türkiye ürtiker tani ve tedavi kilavuzu-2016/The Turkish guideline for the diagnosis and management of urticaria 2016. Turkderm 2016;50:82–98.
- Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101–109.
- Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:67–75.
- Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924–935.
- Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty-five patients. Allergol Int 2018;67:85–89.
- Bulur I, Bulbul Baskan E, Ozdemir M, et al. The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey. Acta Dermatovenerol Alp Pannonica Adriat 2018;27:121–126.
- Wilches P, Wilches P, Calderon JC, et al. Omalizumab for chronic urticaria in Latin America. World Allergy Organ J 2016;9:36.
- Ensina LF, Valle SO, Juliani AP, et al. Omalizumab in chronic spontaneous urticaria: a Brazilian real-life experience. Int Arch Allergy Immunol 2016;169:121–124.
- Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol 2016;175:404–406.
- Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373–1377.
- Bhutani M, Yang WH, Hébert J, et al. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. PLoS One 2017;12:e0183869.